8-KLeadership ChangesOther EventsExhibits & Filings

BOSTON SCIENTIFIC CORP 8-K Report, Executive Changes (May 1, 2007)

Filed May 1, 2007For Securities:BSX

Summary

Boston Scientific Corporation (BSX) filed an 8-K on May 1, 2007, announcing a significant change in its financial leadership. Lawrence C. Best, the current principal financial officer, has informed the company of his intention to retire, with his departure effective July 6, 2007. This marks the end of his tenure and signals a transition period for the company's financial operations. Concurrently, the company announced the appointment of Sam R. Leno as the new Chief Financial Officer and Executive Vice President of Finance and Information Systems, effective June 5, 2007. This strategic hire of Mr. Leno, who will join before Mr. Best's retirement, suggests a planned and smooth handover of critical financial responsibilities, aiming to maintain stability and continuity in financial management and strategic direction.

Key Highlights

  • 1Lawrence C. Best, Principal Financial Officer, announced his intention to retire effective July 6, 2007.
  • 2Sam R. Leno will join Boston Scientific as Chief Financial Officer and Executive Vice President of Finance and Information Systems.
  • 3Sam R. Leno's start date is June 5, 2007, which precedes Mr. Best's retirement.
  • 4The company is undertaking a transition in its top financial executive role.
  • 5The filing includes a press release dated May 1, 2007, detailing these changes as Exhibit 99.1.
  • 6This report addresses Item 5.02 (Departure of Directors or Principal Officers) and Item 8.01 (Other Events).

Frequently Asked Questions

This 8-K filing is primarily to report a change in executive officers. Specifically, it announces the upcoming retirement of the Principal Financial Officer, Lawrence C. Best, and the appointment of Sam R. Leno as the new Chief Financial Officer.

Sam R. Leno's start date of June 5, 2007, is scheduled before Lawrence C. Best's retirement on July 6, 2007. This suggests a deliberate strategy for a smooth transition, allowing for knowledge transfer and overlap in responsibilities to ensure continuity in financial leadership.

Changes in key financial leadership can impact investor confidence and operational continuity. However, the planned transition with an overlap period suggests an effort to mitigate disruption. Investors will likely monitor how the new CFO, Sam R. Leno, influences the company's financial strategy and performance moving forward.

More information regarding Sam R. Leno's appointment and the reasons behind the executive changes is likely contained within the press release issued by Boston Scientific on May 1, 2007, which is attached as Exhibit 99.1 to this 8-K filing.